natgillin/translations-raw huggingface dataset:
For more information about treatment with Ikervis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Ikervis pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
The benefits of Ikervis have been shown in one main study involving 246 patients with severe dry eye disease, where Ikervis was compared with the vehicle (the same eye drop formula but without any active substance). 
Koristi lijeka Ikervis koje su utvrđene u jednom glavnom ispitivanju koje je obuhvatilo 246 bolesnika s ozbiljnom bolesti suhoga oka, pri čemu je Ikervis uspoređen s punilom (ista formula kapljica za oči, no bez bilo kakve djelatne tvari).
The main measure of effectiveness was the proportion of patients whose condition responded to treatment after six months, as measured by a combination of damage to the cornea and a score for the level of symptoms, including discomfort and pain. 
Glavna mjera djelotvornosti bio je udio bolesnika čije je stanje odgovorilo na terapiju nakon šest mjeseci, uključujući nelagodu i bol.
Ikervis is a medicine used to treat severe keratitis, an inflammation of the cornea (the transparent layer covering the front of the eye) in adult patients with dry eye disease. 
Ikervis je lijek koji se koristi za liječenje ozbiljnog keratitisa, upale rožnice (prozirnog dijela koji pokriva prednji dio oka) u odraslih bolesnika s bolesti suhoga oka.
What benefits of Ikervis have been shown in studies? 
Koje su koristi lijeka Ikervis dokazane u ispitivanjima?
How does Ikervis work? 
Kako djeluje Ikervis?
For practical information about using Ikervis, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o korištenju lijeka Ikervis pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
How is Ikervis used? 
Kako se Ikervis koristi?
The medicine must not be used in patients who have or are suspected to have an infection of the eye or the tissues around the eye. For the full list of restrictions, see the package leaflet. 
Lijek se ne smije koristiti u bolesnika koji imaju ili za koje se sumnja da imaju upalu oka ili tkiva oko oka.
The proportion of patients who responded to treatment was therefore similar in the two groups, but when only the damage to the cornea was considered, Ikervis was significantly better than the vehicle at reducing it. Levels of HLADR (a measure of inflammation in eye cells) were also reduced in patients using Ikervis compared with the dummy treatment. 
Udio bolesnika koji su odgovorili na terapiju bio je stoga sličan u obje grupe, no samo ako je se promatralo oštećenje rožnice, Ikervis je bio značajno bolji od punila pri smanjivanju.
For the full list of all side effects reported with Ikervis, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Ikervis potražite u uputi o lijeku.
This will help to protect against the disease. 
Ovo pomaže u zaštiti protiv bolesti.
It is available as a suspension for injection. 
Dostupan je kao suspenzija za injekciju.
Some animals may also have hypersensitivity (allergic) reactions. 
Pojedine životinje mogu također imati i reakcije preosjetljivosti (alergijske reakcije).
After vaccination, animals may have a slightly raised temperature (usually not more than 0.5°C, but in individual cases up to about 2°C) for up to three days after vaccination. 
Nakon cijepljenja, životinje mogu imati blago povišenu temperaturu (najčešće ne više od 0,5°C, no u pojedinačnim slučajevima i do 2°C) i do tri dana nakon cijepljenja.
In all studies the vaccinated cattle and sheep were compared with animals that were not immunised (controls). 
U svim ispitivanjima cijepljena goveda i ovce uspoređene su sa životinjama koje nisu bile imunizirane (kontrole).
The vaccine also contains ‘adjuvants' (aluminium hydroxide and saponin) to enhance the immune response. 
Cjepivo sadrži također „adjuvans” (aluminij hidroksid i saponin) kako bi se pojačao imunosni odgovor.
In the future, if the animals are exposed to the same type of bluetongue virus, the immune system will be able to produce antibodies more quickly. 
U budućnosti, ako životinje budu izložene istom tipu virusa plavog jezika, imunosni sustav moći će brže proizvoditi protutijela.
The virus exists in several forms (serotypes) throughout the world; the type used in Bovilis BTV8 is serotype 8. 
Virus postoji u nekoliko oblika (serotipova) diljem svijeta; tip koji se koristi u Bovilis BTV8 je serotip 8.
Bovilis BTV8 was initially authorised under ‘exceptional circumstances'. 
Bovilis BTV8 je prvotno odobren pod „iznimnim okolnostima”.
This means that it was not possible at the time of the initial authorisation to obtain complete information about Bovilis BTV8. 
To znači da u trenutku prvotnog odobrenja nije bilo moguće dobiti potpune informacije o VMP-u Bovilis BTV8.
The European Medicines Agency (EMA) reviewed additional information according to an agreed timetable on the quality, safety and efficacy of the vaccine. 
Europska agencija za lijekove (EMA) pregledala je dodatne informacije o kvaliteti, sigurnosti i djelotvornosti cjepiva sukladno dogovorenom rasporedu.
One injection is enough to vaccinate sheep, but cattle will need a second injection approximately three weeks later. 
Jedna je injekcija dovoljna za cijepljenje ovaca, no govedima se mora dati druga injekcija nakon otprilike tri tjedna.
The vaccine is given to young animals as an injection under the skin. 
Cjepivo se primjenjuje u mladih životinja kao potkožna injekcija.
When it is given to cattle and sheep, the animals' immune system recognises the virus as ‘foreign' and produce antibodies against it. 
Ako se daje govedima i ovcama, imunosni sustav životinja prepoznaje virus kao „strano tijelo” i proizvodi protutijela protiv virusa.
The main measure of effectiveness was the level of the bluetongue virus in the blood (viraemia) of animals. 
Glavna mjera djelotvornosti bila je koncentracija virusa plavog jezika u krvi (viremija) u životinja.
The European Commission granted a marketing authorisation valid throughout the European Union, for Bovilis BTV8 on 06/09/2010. 
Europska komisija dodijelila je odobrenje za stavljanje u promet koje je na snazi na teritoriju Europske unije za proizvod Bovilis BTV8 dana 06.09.2010.
The vaccine is used to prevent viraemia (the presence of viruses in the blood) in sheep and to limit viraemia in cattle. 
Cjepivo se koristi za sprječavanje viremije (prisutnosti virusa u krvi) u ovaca i za ograničavanje viremije u goveda.
Inactivated adjuvanted vaccine against bluetongue virus serotype 8 
Inaktivirano adjuvantno cjepivo protiv virusa plavog jezika serotipa 8
The efficacy of the vaccine in cattle and sheep was studied in a number of laboratory trials; in cattle from six weeks of age and in sheep from one month of age.. 
Djelotvornost cjepiva u goveda i ovaca ispitana je nizom laboratorijskih testiranja; u goveda u dobi od šest tjedana starosti i u ovaca u dobi od mjesec dana starosti.
The CVMP concluded that the benefits of Bovilis BTV8 exceed the risks and recommended that Bovilis BTV8 be given a marketing authorisation. 
CVMP je zaključio da koristi VMP-a Bovilis BTV8 nadmašuju s njim povezane rizike i preporučio je izdavanje odobrenja za stavljanje u promet VMP-a Bovilis BTV8.
The withdrawal period for both sheep and cattle for meat and milk is zero days. 
Razdoblje karencije kako za ovce tako i za goveda za meso i mlijeko iznosi nula dana.
The risk of bluetongue transmission to cattle following vaccination with Bovilis BTV8 was further investigated in two epidemiological models. 
Rizik od prijenosa plavog jezika na goveda nakon cijepljenja VMP-om Bovilis BTV8 dalje je ispitan na dva epidemiološka modela.
The studies showed that the vaccine is safe for both sheep and cattle and that it prevents viraemia in sheep from one month of age when infected with bluetongue virus serotype 8, whereas Bovilis BTV8 reduces viraemia in cattle from six weeks of age. 
Ispitivanjima je utvrđeno da je cjepivo sigurno kako za ovce tako i za goveda te da sprječava viremiju u ovaca u dobi od mjesec dana starosti u slučaju infekcije virusom plavog jezika serotip 8, dok VMP Bovilis BTV8 smanjuje viremiju u goveda u dobi od šest tjedana starosti.
There can also be a temporary swelling at the injection site, lasting for up to three weeks in sheep and six weeks in cattle. 
Može se pojaviti i privremeno oticanje na mjestu injekcije, koje može potrajati i do tri tjedna u ovaca te šest tjedana u goveda.
The first injection is given from one month of age in sheep and from six weeks of age in cattle. 
Prva se injekcija daje u dobi od jednog mjeseca starosti u ovaca te od šest tjedana starosti u goveda.
The safety of the vaccine was studied in laboratory safety studies carried out with an overdose of Bovilis BTV8 in young lambs and calves and in pregnant ewes and cows. 
Sigurnost cjepiva ispitana je u laboratorijskim ispitivanjima sigurne primjene provedenima s prekomjernom dozom lijeka Bovilis BTV8 u mlade janjadi i teladi te u gravidnih ovaca i krava.
Bovilis BTV8 is used in cattle and sheep to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges. 
Bovilis BTV8 koristi se u goveda i ovaca za zaštitu od bolesti plavog jezika, infekcije koju uzrokuje virus plavog jezika koji se prenosi mušicama.
Bovilis BTV8 contains bluetongue virus that has been inactivated so that it cannot cause the disease. 
Bovilis BTV8 sadrži virus plavog jezika koji je inaktiviran tako da ne može uzrokovati bolest.
The benefit-risk balance may be found in the scientific discussion module of this EPAR. 
Omjer koristi i rizika dostupan je u modulu znanstvene rasprave koji je dio ovog EPAR-a.
Bovilis BTV8 was shown to be safe for use in pregnant ewes and cattle. 
Dokazano je da je Bovilis BTV8 siguran za primjenu u gravidnih ovaca i krava.
Bovilis BTV8 is a vaccine that contains an inactivated (killed) bluetongue serotype 8 virus as the active substance. 
Bovilis BTV8 je cjepivo koje sadrži inaktivirani (ubijeni) virus plavog jezika serotipa 8 kao djelatnu tvar.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat or milk used for human consumption. 
Razdoblje karencije je razdoblje koje treba proći od primjene VMP-a do klanja životinje i uporabe mesa ili mlijeka u prehrani ljudi.
Other information about Bovilis BTV8: 
Druge informacije o VMP-u Bovilis BTV8:
Bovilis BTV8 is a vaccine. 
Bovilis BTV8 je cjepivo.
What is the risk associated with Bovilis BTV8? 
Koji su rizici povezani s VMP-om Bovilis BTV8?
Why has Bovilis BTV8 been approved? 
Zašto je Bovilis BTV8 odobren?
What is Bovilis BTV8? 
Što je Bovilis BTV8?
What benefit has Bovilis BTV8 shown during the studies? 
Koje koristi Bovilis BTV8 su utvrđene tijekom ispitivanja?
What is Bovilis BTV8 used for? 
Za što se Bovilis BTV8 koristi?
How does Bovilis BTV8 work? 
Na koji način Bovilis BTV8 djeluje?
How has Bovilis BTV8 been studied? 
Kako se Bovilis BTV8 ispitivao?
It is given by injection under the skin, once a day. 
Daje se injekcijom pod kožu jednom dnevno.
This summary was last updated in 02-2018. 
Sažetak je posljednji put ažuriran u 02. 2018.
The diagnosis must be confirmed by genetic testing. 
Dijagnoza se mora potvrditi genetskim testiranjem.
• do not grow normally because they do not have enough growth hormone; 
• koja ne rastu normalno jer nemaju dovoljno hormona rasta;
As with all protein medicines, some patients may develop antibodies (proteins that are produced in response to Omnitrope). 
Kao što je slučaj sa svim proteinskim lijekovima, neki bolesnici mogu razviti antitijela (proteine koji se proizvode kao reakcija na lijek Omnitrope).
It must also not be used for promoting growth in children with closed epiphyses (when the large bones have finished growing). 
Ne smije se također primjenjivati za poticanje rasta u djece sa zatvorenim epifizama (kad velike kosti prestanu rasti).
The full EPAR for Omnitrope can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek Omnitrope nalazi se na internetskim stranicama Agencije: website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Children receiving Omnitrope and Genotropin grew at a similar rate of about 10.7 cm per year. 
Djeca koja su primala Omnitrope i Genotropin rasla su sličnom brzinom od oko 10,7 cm na godinu.
• have a genetic condition called Prader-Willi syndrome. 
• s genetskim stanjem pod nazivom Prader-Willijev sindrom.
The dose may need to be adjusted over time, depending on change in body weight and response to treatment. 
Doza će se možda tijekom vremena trebati prilagođavati, ovisno o promjeni tjelesne težine i odgovoru na liječenje.
What is Omnitrope and what is it used for? 
Što je Omnitrope i za što se koristi?
These side effects are uncommon in children (may affect between 1 and 10 patients in 1,000). 
Takve nuspojave manje su česte u djece (u 1 do 10 bolesnika na 1 000).
In adults, side effects related to fluid retention, such as peripheral oedema (swelling, especially of the ankles and feet), paraesthesia (numbness or tingling), joint and muscle pain, and stiffness of the limbs are common (may affect between 1 and 10 patients in 100). 
Nuspojave povezane sa zadržavanjem tekućine, kao što su periferni edem (oticanje, posebno gležnjeva i stopala), parestezija (trnci ili utrnulost), bol u zglobovima i mišićima te ukočenost udova česte su u odraslih osoba (mogu se pojaviti u 1 do 10 na 100 bolesnika).
Somatropin is produced by a method known as ‘recombinant DNA technology': the hormone is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce somatropin. 
Somatropin se proizvodi metodom poznatom pod nazivom „tehnologija rekombinantne DNK”: hormon se stvara od bakterija u koje je uveden gen (DNK) kako bi mogle proizvoditi somatropin.
• are short because they have long-term kidney disease or a genetic disorder called Turner syndrome; 
• koja su niska zbog dugotrajne bolesti bubrega ili genetskog poremećaja koji se naziva Turnerov sindrom;
The deficiency can have started in adulthood or childhood, and needs to be confirmed by testing before treatment. 
Deficit može nastupiti u odrasloj dobi ili u djetinjstvu te se prije liječenja treba potvrditi testiranjem.
The European Commission granted a marketing authorisation valid throughout the European Union for Omnitrope on 12 April 2006. 
Europska komisija izdala je odobrenje za stavljanje lijeka Omnitrope u promet koje vrijedi na prostoru Europske unije od 12. travnja 2006.
The European Medicines Agency considered that, in accordance with EU requirements for biosimilar medicines, Omnitrope has been shown to have a comparable quality, safety and effectiveness to Genotropin. 
Europska agencija za lijekove smatrala je da je, u skladu sa zahtjevima EU-a za bioslične lijekove, lijek Omnitrope pokazao usporedivu kvalitetu, sigurnost i učinkovitost kao i Genotropin.
Omnitrope is given to improve their growth and body composition (by reducing fat and improving muscle mass). 
Omnitrope se daje za poboljšanje njihova rasta i građe tijela (smanjenjem masnog tkiva i povećanjem mišićne mase).
This means that Omnitrope is highly similar to a biological medicine (the ‘reference medicine') that is already authorised in the EU. 
Drugim riječima, lijek Omnitrope vrlo je sličan biološkom lijeku („referentnom lijeku”) koji je već odobren u EU-u.
Results showed that, after treatment for 9 months, Omnitrope was as effective as Genotropin in improving growth. 
Rezultati su pokazali da je nakon devet mjeseci liječenja Omnitrope bio jednako djelotvoran kao i Genotropin u poboljšanju rasta.
The doctor calculates the dose for each patient individually according to the body weight and the condition being treated. 
Dozu izračunava liječnik za svakog bolesnika posebno, u skladu s tjelesnom težinom i stanjem koje se liječi.
Omnitrope was compared with Genotropin in 89 children with a lack of growth hormone who had not been treated before. 
Omnitrope je uspoređen s lijekom Genotropin u 89 djece s nedostatkom hormona rasta koja prethodno nisu liječena.
This is a summary of the European public assessment report (EPAR) for Omnitrope. 
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Omnitrope.
• are short and were born small for their gestational age, and have not caught up by the age of 
• koja su niska i rođena mala za svoju gestacijsku dob te koja nisu uspjela nadoknaditi zaostajanje u rastu do dobi od 4 godine ili kasnije;
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Omnitrope have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Omnitrope nalaze se u sažetku opisa svojstava i u uputi o lijeku.
Other information about Omnitrope 
Ostale informacije o lijeku Omnitrope
Therefore, the Agency's view was that, as for Genotropin, the benefit outweighs the identified risk and it recommended that Omnitrope be given marketing authorisation. 
Stoga je mišljenje Agencije da, kao i kod lijeka Genotropin, koristi nadmašuju utvrđene rizike te je preporučila davanje odobrenja za stavljanje lijeka Omnitrope u promet.
It is important for growth during childhood and adolescence, and it also affects how the body handles proteins, fat and carbohydrates. 
Ona je važna za rast u djetinjstvu i u odrasloj dobi te utječe i na metabolizam bjelančevina, masti i ugljikohidrata u tijelu.
Omnitrope is also used as replacement therapy in adult patients with pronounced growth hormone deficiency. 
Omnitrope se također primjenjuje kao nadomjesna terapija u odraslih bolesnika s izraženim deficitom hormona rasta.
Omnitrope can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with growth disorders. 
Omnitrope se izdaje samo na liječnički recept, a liječenje treba započeti i nadzirati liječnik s iskustvom u liječenju bolesnika s poremećajima rasta.
The reference medicine for Omnitrope is Genotropin. 
Referentni lijek za lijek za Omnitrope je Genotropin.
Omnitrope must not be used if the patient has an active tumour or an acute life-threatening illness. 
Omnitrope ne smiju uzimati bolesnici koji imaju aktivan tumor ili akutnu bolest opasnu po život.
Omnitrope is a medicine used to treat children who: 
Omnitrope je lijek koji se primjenjuje u liječenju djece:
For more information about treatment with Omnitrope, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Omnitrope pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
What measures are being taken to ensure the safe use of Omnitrope? 
Koje se mjere poduzimaju kako bi se osigurala sigurna primjena lijeka Omnitrope?
The Omnitrope cartridges should only be used with the special Omnitrope injection device. 
Ulošci s lijekom Omnitrope trebali bi se upotrebljavati samo s posebnom injekcijskom napravom za Omnitrope.
What are the risks associated with Omnitrope? 
Koji su rizici povezani s lijekom Omnitrope?
The active substance in Omnitrope, somatropin, is identical to the human growth hormone, which it replaces. 
Djelatna tvar u lijeku Omnitrope, somatropin, identična je ljudskom hormonu rasta koji zamjenjuje.
The patient or caregiver can inject Omnitrope, after being trained by a doctor or a nurse. 
Omnitrope mogu ubrizgati bolesnik ili pružatelj skrbi nakon što su ih za to obučili liječnik ili medicinska sestra.
It is not intended to provide practical advice on how to use Omnitrope. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Omnitrope.
The medicine is available as a powder and solvent, which are made up into a solution for injection, or as a ready-to-use solution in a cartridge. 
Lijek je dostupan u obliku praška i otapala za otopinu za injekciju ili u obliku gotove otopine u ulošku.
Why is Omnitrope approved? 
Zašto je lijek Omnitrope odobren?
Omnitrope contains the active substance somatropin and is a ‘biosimilar' medicine. 
Omnitrope sadržava djelatnu tvar somatropin te je „biosličan lijek”.
Growth hormone is released by the pituitary gland (a gland at the base of the brain). 
Hormon rasta izlučuje hipofiza (žlijezda koja se nalazi u bazi mozga).
For practical information about using Omnitrope, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Omnitrope bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
What benefits of Omnitrope have been shown in studies? 
Koje su koristi lijeka Omnitrope utvrđene u ispitivanjima?
Omnitrope was studied to show that it is comparable to the reference medicine, Genotropin. 
Lijek Omnitrope ispitivan je kako bi se pokazala njegova usporedivost s referentnim lijekom, Genotropin.
How does Omnitrope work? 
Kako djeluje Omnitrope?
Howeve,r these antibodies do not have an effect on how well Omnitrope works. 
Međutim, ta antitijela ne utječu na djelotvornost lijeka Omnitrope.
How is Omnitrope used? 
Kako se Omnitrope koristi?
For the full list of side effects of Omnitrope, see the package leaflet. 
Potpuni popis nuspojava lijeka Omnitrope potražite u uputi o lijeku.
H-1114 Budapest Hungary 
H-1114 Budapest
LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
POPIS NAZIVA, FARMACEUTSKIH OBLIKA, JAČINA LIJEKOVA, PUTEVA PRIMJENE,
2-4, rue Lionel Terray 92500 RUEIL-MALMAISON, France 
Francuska Novartis Pharma S.A.S. 2-4, rue Lionel Terray 92500 RUEIL-MALMAISON, France
Novartis Farmacéutica S.A. Gran Via de les Corts Catalanes, 764 
Španjolska Novartis Farmacéutica S.A. Gran Via de les Corts
2- 4, rue Lionel Terray 92500 RUEIL-MALMAISON, France 
Francuska Novartis Pharma S.A.S. 2- 4, rue Lionel Terray 92500 RUEIL-MALMAISON, France
100mg/cap Capsule, soft 
100mg/cap Kapsula, meka
50mg/cap Capsule, soft 
50mg/cap Kapsula, meka
Novartis Hungária Kft. Pharma részlege 
Mađarska Novartis Hungária Kft.
25mg/cap Capsule, soft 
25mg/cap Kapsula, meka
International non-proprietary name (INN): eprinomectin 
Međunarodni nezaštićeni naziv (INN): eprinomektin
Article 33(4) of Directive 2001/82/EC, as amended 
Članak 33. stavak 4. Direktive 2001/82/EZ, s izmjenama
The decentralised procedure started on 21 February 2012. 
Decentralizirani postupak započet je dana 21. veljače 2012. godine.
The opinion was converted into a Decision by the European Commission on 21 March 2014. 
Europska komisija usvojila je mišljenje u obliku Odluke dana 21. ožujka 2014.
The referral procedure started on 15 May 2013. 
Postupak upućivanja započet je dana 15. svibnja 2013. godine.
Potential serious risks were identified during the decentralised procedure by Germany regarding the environmental safety of the product. 
Tijekom decentraliziranog postupka, Njemačka je identificirala potencijalne ozbiljne rizike vezane uz okolišnu sigurnost VMP-a.
Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle contains eprinomectin as an active substance and is intended for use in cattle as a topical application for the treatment and control of infections from gastrointestinal roundworms (adults and fourth stage larvae), lungworms (adults and fourth stage larvae), warbles (parasitic stages), mange mites, lice and horn flies. 
Norbonex 5 mg/ml otopina za polijevanje po koži goveda i mliječnih pasmina stoke sadrži eprinomektin kao djelatnu tvar i predviđena je za uporabu u stoke za topikalnu primjenu za liječenje i kontrolu infekcija uzrokovanih gastrointestinalnim oblićima (odraslima i u četvrtom stupnju ličinke), plućnim vlascima (odraslima i u četvrtom stupnju ličinke), štrkovima (stupnjevima parazita), šugarcima, ušima i rožnim muhama.